(S,S)-SARM1-IN-9 (Compound MY-13A) is a stereoselective SARM1 inhibitor with covalent binding properties. (S,S)-SARM1-IN-9 covalently modifies Cys311 in the autoregulatory ARM domain of wild-type SARM1, thereby blocking NADase activity, without inhibiting the SARM1C311A or SARM1C311S mutants. (S,S)-SARM1-IN-9 blocks vacor- and vincristine-induced axon degeneration in primary rodent dorsal root ganglion neurons. (S,S)-SARM1-IN-9 can be used for research on axon degeneration-dependent neurological disorders, including chemotherapy-induced peripheral neuropathy.

(S,S) Bisoleoyl-lysobisphosphatidic acid is a lysobisphosphatidic acid (LBPA). LBPA plays a role in modulating the cholesterol flux through endosomes.

(S,R,S,R)-AHPC-Me-CO-C7-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S,R)-AHPC-Me based VHL ligand and a linker used in PROTAC technology. (S,R,S,R)-AHPC-Me-CO-C7-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-28.

(S,R,S)-BBO-11818 (compound 59) is an inhibitor of KRAS that can be used in the research of cancer.

(S,R,S)-AHPC-Me-NHBoc is an E3 ubiquitin ligase VHL ligand used to recruit the VHL protein. (S,R,S)-AHPC-Me-NHBoc can be linked to a target protein ligand via a linker to form a PROTAC.

(S,R,S)-AHPC-Me-amide-C-O-PEG2-COOH is an E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-amide-C-O-PEG2-COOH can be used for synthesis of PROTACs.

(S,R,S)-AHPC-CO-PEG3-NHBoc is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC G9a/GLP degrader 1. PROTAC G9a/GLP degrader 1 is a potent G9a/GLP PROTAC degrader with anti-cancer activity.

(S)-Oxybutynin is a pharmaceutical intermediate. (S)-Oxybutynin can synthesize antifungal agents.

(S)-LY-41, R-enantiomer of LY-41, is 2-Sminotetralin derivative and 8-OH-DPAT analogue. (S)-LY-41 is a potent and selective 5-HT1A receptor agonist. (S)-LY-41 can reduce the accumulation of 5-hydroxytryptophan (the precursor for 5-HT synthesis) in the rat brain induced by decarboxylase inhibitors (NSD 1015). (S)-LY-41 can lower the body temperature of rats and inhibit the escape response from the cage. (S)-LY-41 can induce the 5-HT behavioral syndrome. (S)-LY-41can be used for the research of neurological disease, such as depression and anxiety.

(S)-JQ-35-Boc is a BRD4 ligand. (S)-JQ-35-Boc can be used to synthesize BRD4 degrader RAJQ14. RAJQ14 can be used for cancer research.

(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib. (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia.

(S)-2-Ketodoxapram ((S)-AHR 5955) is a metabolite of Doxapram. Doxapram is a respiratory stimulant[1][2].

(rel)-PRT062607 ((rel)-P505-15) is the relative configuration of PRT062607. PRT062607 is a highly selective inhibitor of Syk kinase, with an IC50 value of 1-2 nM, and is more than 80 times less potent against Fgr, Lyn, FAK, Pyk2, and Zap70.

(rel)-Nutlin carboxylic acid is the Nutlin 3-based MDM2 ligand. (rel)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTAC.

(Rac)-UCB-J (Compound 23) is a ligand for synaptic vesicle protein 2A (SV2A), with a pIC50 value of 8.2. (Rac)-UCB-J can be used as a PET tracer for SV2A to assist in the diagnosis of epilepsy research.

(Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib. Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.

(Rac)-GSK2973980A (Compound 215) is a DGAT1 inhibitor with an IC50 of 1.8 nM for hDGAT1. (Rac)-GSK2973980A can be used for research on obesity and obesity-related diseases.

(Rac)-GK563 is the isomer of GK563. GK563 is a Ca2+-independent group VI phospholipase A2 (GVIA iPLA2) inhibitor.

(Rac)-Azide-deoxy-ascomycin-O-ethylene, a nitrogen-containing compound, is a derivative of a macrolide-type immunosuppressant.

(Rac)-[6]-Gingerol is a natural product. (Rac)-[6]-Gingerol can be isolated from rhizomes of Z. officinale. (Rac)-[6]-Gingerol shows moderate anticancer activity against lung cancer, ovarian cancer, melanoma, and colon cancer.

(R,R)-Birelentinib ((R,R)-DZD8586) (Compound 14) is a potent BTK inhibitor with IC50 values for BTK WT and BTK C481S of 0.7 and 0.86 nM, respectively. (R,R)-Birelentinib inhibits the self-phosphorylation of BTK and its IC50 is 24.3 nM. (R,R)-Birelentinib exhibits significant anti-proliferative activity against wild-type and C481S mutant HEK293 cells. (R,R)-Birelentinib can be used for the study of drug-resistant B-cell malignancies.

(R)-Ureidoisobutyric acid is a nucleoside metabolite.

(R)-SM875 is a degrader targeting the intermediate folding form of prion protein (PrP). (R)-SM875 significantly reduces the PrP level, with an IC50 of 3 μM. (R)-SM875 can be used for the study of prion diseases.

(R)-SLB1122168 free base, an isomer of SLB1122168 free base, is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM.

(R)-SCH-23982 hydrochloride is the R-enantiomer of SCH-23982 hydrochloride. SCH-23982 hydrochloride is a selective dopamine D1 receptor antagonist. (R)-SCH-23982 hydrochloride is promising for research of central nervous system disorders such as schizophrenia, Parkinson’s disease.

(R)-DRF053 is a CDK inhibitor. (R)-DRF053 inhibits Cdk5 and promotes the formation of ductal precursor β cells. (R)-DRF053 inhibits Dil-ox-LDL uptake and CD36 gene expression induced by advanced glycation end products (AGEs) in U937 cells.

(R)-6-Hydroxybuspirone is a metabolite of the anxiolytic agent Buspirone. (R)-6-Hydroxybuspirone itself also has anxiolytic activity.

(M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses MPro inhibitor with an IC50 of 2.5 nM aginst SARS-CoV-2 MPro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection.

(E/Z)-YLF-466D (E/Z)-C24) is a AMPK activator. (E/Z)-YLF-466D directly activates AMPK, a key regulator of energy homeostasis. (E/Z)-YLF-466D activates p53 and regulates proliferation signaling pathways in cancer cells. (E/Z)-YLF-466D exhibits anti-tumor activity.

(E,E)-ATSM is a chelating agent. (E,E)-ATSM can react with the metallized ligand Copper gluconate. (E,E)-ATSM can be used in research on central nervous system diseases.